Overview

Synchron develops brain-computer interface (BCI) technology that enables individuals, particularly those with severe paralysis, to control digital devices using their thoughts. Their main product involves a minimally invasive endovascular procedure for implanting the BCI, which is similar to placing stents and avoids the need for open brain surgery. This approach makes the technology safer and more accessible for patients with neurological conditions that limit their ability to communicate or move. Unlike competitors, Synchron focuses on a less invasive method of BCI implantation, which can lead to quicker recovery times and broader patient eligibility. The company's goal is to enhance patient autonomy and social connection by providing them with the ability to interact with technology through thought, ultimately transforming their quality of life.

Simplify's Take

What believers are saying

• Growing interest in non-invasive BCIs positions Synchron as a preferred option.
• AI integration with NVIDIA enhances Synchron's BCI functionality and patient care.
• Telehealth trends support Synchron's remote device control and patient autonomy.

What critics are saying

• Competition from Neuralink may impact Synchron's market share and innovation.
• Ethical concerns about brain data privacy could hinder Synchron's technology adoption.
• Regulatory challenges may delay Synchron's AI and neural interface product launches.

What makes Synchron unique

• Synchron offers a minimally invasive BCI, unlike competitors requiring open brain surgery.
• The company's BCI technology allows thought-based control of digital devices for paralyzed patients.
• Synchron's Chiral(TM) is the world's first cognitive AI brain foundation model.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$134.3M

Above

Industry Average

Funded Over

5 Rounds

$75,000,000

Series C

Dec 2022

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.

Series C Funding Comparison

Above Average

Industry standards

Ind Avg. $50M

$16M

$40M

$50M

$62M

$75M

$100M

View all funding stages